CANbridge Pharmaceuticals Inc.

📍 Burlington, United States🗓 Founded 2012👥 61 employees💰 Last funded May 2020
Pharmaceutical Manufacturing🌐 canbridgepharma.com
Website LinkedIn
CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, it has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib), in greater China, as well as rights to other novel candidates.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in CANbridge Pharmaceuticals Inc.?
CANbridge Pharmaceuticals Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did CANbridge Pharmaceuticals Inc. last raise funding?
The most recent investment in CANbridge Pharmaceuticals Inc. recorded on gritt.io was in May 2020.
When was CANbridge Pharmaceuticals Inc. founded?
CANbridge Pharmaceuticals Inc. was founded in 2012.
What industry is CANbridge Pharmaceuticals Inc. in?
CANbridge Pharmaceuticals Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is CANbridge Pharmaceuticals Inc. based?
CANbridge Pharmaceuticals Inc. is headquartered in Burlington, United States.